CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cellyan Biotechnology (Nasdaq: HKPD) regained compliance with Nasdaq’s minimum bid price requirement, resolving its previously disclosed listing deficiency.
Nasdaq confirmed compliance in a written notification received on November 13, 2026. The company’s Class A ordinary shares maintained a closing bid price of at least US$1.00 for 14 consecutive business days, from October 26 through November 12, 2026. Nasdaq closed the matter. The original deficiency notice was issued on January 12, 2026, after the shares closed below US$1.00 for 30 consecutive business days. An extension had given the company until January 11, 2027, to regain compliance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNasdaq minimum bid price compliance regained; the matter was closed following 14 consecutive business days at or above US$1.00.
Negative
- None.
Key Figures
- Minimum closing bid price
- at least US$1.00 per share
- Nasdaq minimum bid price requirement
- Compliance period achieved
- 14 consecutive business days
- October 26 through November 12, 2026
- Required compliance duration
- 10 consecutive business days
- Minimum period at or above the required bid price
Historical Context
-
Announced a planned 1-for-20 reverse split as a compliance measure.
-
Received an additional compliance period through January 11, 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market.
As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary shares had been below US
Subsequently, on November 13, 2026, Nasdaq determined that the closing bid price of the Company’s Class A ordinary shares was at least US
About Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.
Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.
For investor and media inquiries please contact:
Cellyan Biotechnology Co., Ltd
Media Contact: andy@cell-yan.com
Investor Relations: stella@cell-yan.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.